Announcement under Regulation 30 (LODR) Regulations, 2015 regarding issuance of Press Release viz. "Dr. Reddy''s Laboratories Launches its Generic Semaglutide Injection in Canada".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Reddy's has launched its generic Semaglutide Injection in Canada following Health Canada approval on April 28, 2026. The company was the first to receive regulatory clearance for a generic version of this GLP-1 therapy in Canada, which is also the first G7 country to authorize generic Semaglutide. The product is indicated for once-weekly treatment of type 2 diabetes in adults, available in 2mg and 4mg pre-filled pen formulations. CEO Erez Israeli highlighted the milestone and noted the company is actively working to expand access to GLP-1 therapies across multiple global markets, building on a recent India launch under the brand name Obeda.
This launch represents a significant regulatory milestone as the first generic Semaglutide approved in a G7 country, potentially opening a major market for Dr. Reddy's GLP-1 portfolio, though specific revenue impact is not disclosed.